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Protecting Investigators from Exposure to Bacillus anthracis Using 
Personal Protective Equipment
NIOSH personnel and other investigators at risk for exposure to Bacillus anthracis, the organism causing anthrax, 
should wear protective personal equipment (PPE), including respiratory devices, protective clothing, and gloves. 
The items described below are similar to those used by emergency personnel responding to incidents involving 
letters or packages. Responders need to use greater levels of protection in responding to incidents involving 
unknown conditions or those involving aerosol-generating devices.
P ow ered  A ir-Purifying R esp irator w ith  Full F acep iece and  
H igh-E nergy P articu late  
Air (HEPA) F ilters
• The constant flow of clean air into the facepieces is an important feature of this respirator because 
contaminated air cannot enter gaps in the face to facepiece seal. These respirators also give wearers needed 
mobility and field of vision.
• Use respirators in accordance with a respiratory-protection program that complies with the OSHA respiratory- 
protection standard (29 C FR  1910.134).
• Respiratory facepieces for NIOSH investigators will be assigned on the basis of results of quantitative fit 
testing.
• Wearing a properly functioning, powered, air-purifying respirator with a full facepiece that is assigned to the 
wearer on the basis of quantitative fit testing will reduce inhalation exposures to 2 % or less of what they 
would be without wearing this type of respirator.
Disposable Protective Clothing with Integral Hood and Booties
• Wearing protective clothing not only protects the skin but can eliminate the likelihood of transferring 
contaminated dust to places away from the work site.
• Wear disposable rubber shoe coverings with ridged soles made of slip-resistant material over the booties of 
the disposable suit to reduce likelihood of slipping on wet or dusty surfaces.
• Decontaminate all P P E  immediately after leaving a potentially contaminated area.
Remove and discard protective clothing before removing the respirator.
Disposable Gloves
• Disposable gloves made of lightweight nitrile or vinyl protect hands from contact with potentially contaminated 
dusts with compromising needed dexterity.
• A  thin cotton glove can be worn inside a disposable glove to protect against dermatitis, which can occur from 
prolonged exposure of the skin to moisture in gloves caused by perspiration.
C onc lu s ions
• The current B. anthracis strains associated with the intentional exposures are susceptible to ciprofloxacin and 
doxycycline, the two drugs approved for post-exposure prophylaxis to B. anthracis and recommended as part 
of initial therapy of inhalational or cutaneous anthrax.
• The current strains also are susceptible to chloramphenicol, clindamycin, rifampin, vancomycin, and 
clarithromycin, but limited or no data exists regarding the use of these agents in the treatment or prophylaxis 
of B. anthracis infections.
• Cephalosporins should not be used for post-exposure prophylaxis or treatment ofB. anthracisinfections.
• The likelihood of a beta-lactamase induction event that would increase penicillin MICs is significantly higher in 
infections where high concentrations of organisms are present. Thus, treatment of known B. anthracis 
infections with a penicillin type drug alone (i.e., penicillin G, ampicillin, etc.)in the setting where high 
concentrations of organisms are present is a concern.
• The likelihood of a beta-lactamase induction event that would increase penicillin MICs is lower when only 
small numbers of vegetative cells are present, such as during post exposure prophylaxis. Thus, amoxicillin or 
penicillin VK  may be an option for post-exposure prophylaxis where ciprofloxacin or doxycycline are 
contraindicated.
• Additional studies are in progress to assess the susceptibility of the penicillinase activity observed in these 
strains to beta-lactamase inhibitors.
• Clinical experience is limited, but combination therapy with two or more antimicrobials may be appropriate in 
patients with severe infection.
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